{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-003287","form_type":"8-K","ticker":"OMER","cik":"0001285819","company_name":"OMEROS CORP","filed_at":"2024-02-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.683618+00:00","generated_at":"2026-06-06T06:44:50.306383+00:00","sec_items":["1.01","2.03"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Omeros amends royalty deal with DRI, receives $115M for expanded OMIDRIA royalty sale","bullets":["Omeros received $115M cash from DRI Healthcare Acquisitions LP for an expanded interest in OMIDRIA royalties.","Amendment eliminates annual caps on DRI royalties; DRI now receives all U.S. net sales royalties from Jan 2024 through Dec 2031.","Omeros eligible for two milestone payments of up to $27.5M each in Jan 2026 and Jan 2028 based on U.S. sales thresholds.","Omeros retains all non-U.S. OMIDRIA royalties from Jan 2024 and all global royalties after Dec 2031; royalty term extends to 2035 in U.S."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-003287","json":"https://secwatch.observer/filing/0001437749-24-003287.json","markdown":"https://secwatch.observer/filing/0001437749-24-003287.md","text":"https://secwatch.observer/filing/0001437749-24-003287.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1285819/000143774924003287/0001437749-24-003287-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1285819/000143774924003287/omer20230913_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T06:44:50.306383+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}